EQS-News

BRAIN Biotech AG: BRAIN Biotech AG´s Akribion Genomics team wins first prize at the “BioRiver Boost!” startup competition

EQS-News: BRAIN Biotech AG / Key word(s): Miscellaneous BRAIN Biotech AG: BRAIN Biotech AG´s Akribion Genomics team wins first prize at the “BioRiver Boost!” startup competition 28.09.2023 / 10:30 CET/CEST The issuer is solely responsible for the content of this announcement.

---

BRAIN Biotech AG´s Akribion Genomics team wins first prize at the “BioRiver Boost!” startup competition

Zwingenberg (Germany), 28 September 2023 – BRAIN Biotech AG is pleased to announce that its Akribion Genomics team has won the first prize in the “BioRiver Boost! 2023” startup competition for life science founders. The jury awarded the prize for the team’s pitch presentation and overall concept to turn CRISPR-based cell killing tools into a new therapeutics approach for oncology. This year’s “BioRiver Boost!” was the 10^th instalment of the annual startup competition for European startups across all life science fields.

The Akribion Genomics team is developing cytotoxic nucleases into a new class of guided cancer therapies and advanced genome editing tools, today powered by the BRAIN Biotech AG BioIncubator. Due to the novel mode of action of its proprietary nuclease G-dase E (previously termed “BEC”), the Akribion Genomics team is capable of developing visionary options for novel therapeutic applications. This potential was recognized during the “BioRiver Boost!” competition, in which Akribion Genomics was selected to be among the 8 finalists to present their pitch in person. The final pitches round took place on September 22^nd, 2023. It was hosted by Bayer Crop Science in their LifeHub in Monheim am Rhein.

Adriaan Moelker, CEO of BRAIN Biotech AG, comments: "Congratulations to our colleagues in the Akribion Genomics team, who have developed the concept over the last years and are currently working hard to bring it to life. This award further underscores the commercial relevance of our proprietary G-dase technology, in therapeutics and beyond. We remain in active discussions with potential financial and strategic partners to accelerate therapeutic applications within Akribion Genomics, with the intention to found a separate legal entity. BRAIN Biotech will also continue to use the technology for the benefit of its customers from industry.”